Effect of XXXX in @entity365 : a double-blind clinical trial versus @entity1449 .

@entity1 @entity1449 @entity137 @entity304 @entity8304 @entity7553 @entity14407 @entity5132 @entity365
@entity14407 is an @entity8304 derivative which possesses a broad spectrum antimycotic activity, including activity against @entity5132 . Its therapeutic activity and tolerability have been evaluated, in a double-blind clinical trial versus @entity1449 , in 54 @entity1 affected by mycologically confirmed symptomatic @entity365 . Both drugs were administered intravaginally as a cream once a day for 7 days. Assessment was by laboratory mycological investigations and symptomatic evaluation. @entity1 'cured' at the end of the trial were re-evaluated after 4-6 weeks for possible relapses. Both treatments resulted in a progressive, statistically significant @entity304 (itching and discharge) and in elimination of Candida in more than 95% of @entity1 . When 'cured' @entity1 were reassessed 4-6 weeks after therapy, relapses occurred in four @entity1 after @entity14407 treatment, but in none following @entity1449 treatment. This apparent difference between treatments is far from being statistically significant and, therefore, may have been a chance occurrence. It should also be noted that @entity1 from the @entity14407 group had a previous history of significantly more frequent episodes of @entity7553 suggesting that they may have been at greater risk of re-infection than @entity1 from the control group. The tolerance of both treatments was excellent since no local or systemic signs or symptoms of @entity137 were reported. An equally high efficacy and safety for both drugs in the elimination of symptoms and objective evidence of @entity365 is indicated.
